The First Affiliated Hospital of Zhengzhou University clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 124 studies whose lead sponsor is The First Affiliated Hospital of Zhengzhou University. 72 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Keep track of what changes. Save the The First Affiliated Hospital of Zhengzhou University studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Where
- China
- 101
Focus areas
Conditions The First Affiliated Hospital of Zhengzhou University leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 124. Browse all 124 →
- A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ AdenocarcinomaNot yet recruitingNCT07828873Phase 2
- Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic CancerNot yet recruitingNCT07814859Phase 2
- PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric CancerRecruitingNCT07294664Phase 2
- A Prospective, Multicenter, Randomized Controlled Trial Investigating the Impact of Fasting Duration on Postoperative Rebleeding Following Esophageal Variceal Ligation.RecruitingNCT07774143Not applicable
- Standardized MRI and Structured Reporting for Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07769658
- A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric CancerRecruitingNCT07770113Phase 2
- Pro-urokinase for Extended-Window Posterior Circulation StrokeNot yet recruitingNCT07617870Phase 3
- Newborns From Patients Treated With ART (Assisted Reproductive Technology)RecruitingNCT03993158
- A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory GliomaRecruitingNCT07599371Phase 1/2
- Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR MismatchNot yet recruitingNCT07540416Phase 3
- Effect of a Novel Colonoscopic Lavage Solution on Colonoscopy QualityNot yet recruitingNCT07501975Not applicable
- Effect of Intraluminal Administration of Menthol Solution During Colonoscopy on Colonic Spasm and Adenoma Detection RateNot yet recruitingNCT07501962Not applicable
- Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion LesionsRecruitingNCT07463664Not applicable
- The Effect of Blood Flow Restriction Training Combined With Transcranial Magnetic Stimulation on Limb Function in Hemiplegic Patients After StrokeNot yet recruitingNCT07454954Not applicable
- A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07446335Phase 3
- IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric CancerNot yet recruitingNCT07361991Phase 1/2
- Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingNCT07314619Phase 2
- Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.RecruitingNCT07169656
- A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07128693Phase 2
- Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLCRecruitingNCT06896422Phase 1
- Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical CancerRecruitingNCT07104149Phase 2
- Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric CancerNot yet recruitingNCT07085273Phase 2
- Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell CancerRecruitingNCT07016724Phase 2
- Prognostic Value of Neurometabolic Networks in CRC (PVNM-CRC)RecruitingNCT06930586
- NR vs. Vitamin E in Enhancing FertilityNot yet recruitingNCT06950736Not applicable
- A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence RiskRecruitingNCT06930573Phase 4
- Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic CholangiocarcinomaEnrolling by invitationNCT06901622Phase 2
- Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre SyndromeNot yet recruitingNCT05114941Not applicable
- Energy CT in Imaging and Diagnosis of Gastric CancerRecruitingNCT06869694
- A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALLRecruitingNCT06557161Phase 2
- A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALLRecruitingNCT06564493Phase 2
- A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALLRecruitingNCT06559345Phase 2
- A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALLRecruitingNCT06564545Phase 2
- Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal CancerNot yet recruitingNCT06760520Phase 2
- Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the BrainRecruitingNCT06747728Not applicable
- Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs TherapyNot yet recruitingNCT06746961Phase 1/2
- Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06718205Phase 2
- Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCCRecruitingNCT05738434Phase 2
- Effects of ITBS Combined with NMES on Dysphagia After StrokeEnrolling by invitationNCT06464835Not applicable
- A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT03736863Phase 2
- RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric CancerNot yet recruitingNCT06492317Phase 2
- Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJCNot yet recruitingNCT06439550Phase 2
- Effect of Botulinum Toxin Injection Guided by Ultrasound Combined With Balloon Localization on Cricopharyngeal AchalasiaRecruitingNCT06213662Not applicable
- Effect of Botulinum Toxin Injection Into Upper Esophageal Sphincter in Patients With Medullary InfarctionRecruitingNCT06196606Not applicable
- Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung CancerRecruitingNCT06341530Phase 2
- Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal CancerRecruitingNCT06231017Phase 2
- Cortical Function Changes During Swallowing in Patients With Dysphagia in Lateral Medullary SyndromeRecruitingNCT06208020
- Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 StageRecruitingNCT06194981
- Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective StudyRecruitingNCT06194968
- IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)Not yet recruitingNCT06078657Phase 2